The impact of COVID-19 on lung cancer detection, diagnosis and treatment for Māori in Aotearoa New Zealand.


Journal

The New Zealand medical journal
ISSN: 1175-8716
Titre abrégé: N Z Med J
Pays: New Zealand
ID NLM: 0401067

Informations de publication

Date de publication:
10 06 2022
Historique:
entrez: 21 6 2022
pubmed: 22 6 2022
medline: 24 6 2022
Statut: epublish

Résumé

The purpose of this article is to examine disparities in the impact of the COVID-19 pandemic on access to lung cancer diagnosis and access to clinical services between Māori and non-Māori. Using national-level data, we examined age-standardised lung cancer registrations, diagnostic procedures (bronchoscopy) and lung surgeries separately by ethnic group for the years 2018-2020, as well as patterns of stage of diagnosis. We found a trend toward a reduction in rates of lung cancer registration in Māori (but not non-Māori/non-Pacific) New Zealanders in 2020 compared to 2018 and 2019, but no apparent shift in the distribution of stage at diagnosis. We found a trend toward a reduction in rates of bronchoscopy for both Māori and non-Māori/non-Pacific patients, with the largest reduction observed for Māori. Rates of lung cancer surgery appeared to have reduced for Māori patients, although this was based on a small number of procedures. We observed disparities between Māori and non-Māori/non-Pacific patients in lung cancer registration and bronchoscopy as a result of the COVID-19 pandemic.

Identifiants

pubmed: 35728246

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

23-43

Déclaration de conflit d'intérêts

Nil.

Auteurs

Jason K Gurney (JK)

Te Aho o Te Kahu - Cancer Control Agency, Wellington, New Zealand; Department of Public Health, University of Otago, Wellington, New Zealand.

Alex Dunn (A)

Te Aho o Te Kahu - Cancer Control Agency, Wellington, New Zealand.

Michelle Liu (M)

Te Aho o Te Kahu - Cancer Control Agency, Wellington, New Zealand.

Michelle Mako (M)

Te Aho o Te Kahu - Cancer Control Agency, Wellington, New Zealand.

Elinor Millar (E)

Te Aho o Te Kahu - Cancer Control Agency, Wellington, New Zealand.

Myra Ruka (M)

Te Aho o Te Kahu - Cancer Control Agency, Wellington, New Zealand.

Sue Crengle (S)

Department of Preventive and Social Medicine, University of Otago, Dunedin, New Zealand.

Paul Dawkins (P)

Counties-Manukau District Health Board, Auckland, New Zealand.

Christopher Jackson (C)

Southern District Health Board, Dunedin, New Zealand; Department of Medicine, University of Otago, Dunedin, New Zealand.

George Laking (G)

Auckland District Health Board, Auckland, New Zealand; Northland District Health Board, Whangārei, New Zealand.

Diana Sarfati (D)

Te Aho o Te Kahu - Cancer Control Agency, Wellington, New Zealand.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH